ACME LaboratoriesDHA:ACMELAB +0.37%82 Net Margin % is 6.68% as of Mar. 2026, which is 23% below its 10-year median of 8.71. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, ACME Laboratories ranks better than 53.87% on this metric.
The historical rank and industry rank for ACME Laboratories's Net Margin % or its related term are showing as below:
DHA:ACMELAB'
s Net Margin % Range Over the Past 10 Years
Min: 6.53 Med: 8.71 Max: 10.3
Current: 6.53
DHA:ACMELAB's Net Margin % is ranked better than 53.87% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs DHA:ACMELAB: 6.53
ACME Laboratories (DHA:ACMELAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ACME Laboratories Net Margin % Related Terms
ACME Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Net Margin % of 6.68% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ACME Laboratories and its competitors. This is 23% below median its historical median of 8.71. Over the past decade, ACME Laboratories' Net Margin % has ranged from 6.53 to 10.30. According to the industry distribution chart, ACME Laboratories ranks #441 out of 956 companies in the Drug Manufacturers industry, placing it in the top 46.1%.
Is ACME Laboratories' Net Margin % too high?
ACME Laboratories' current Net Margin % of 6.68% is 23% below median its 10-year median of 8.71. Over the past 10 years, this metric has ranged from a low of 6.53 to a high of 10.30. The Drug Manufacturers industry median Net Margin % is 5.56. ACME Laboratories' value of 6.68% is 20.1% above this industry median. Based on the distribution chart, ACME Laboratories ranks #441 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #441 out of 956 companies for Net Margin %. This puts ACME Laboratories in the upper half of its industry. The industry median Net Margin % is 5.56. ACME Laboratories' value of 6.68% is 20.1% above this benchmark. Historically, ACME Laboratories' own Net Margin % has ranged from 6.53 to 10.30 over the past decade. While the company's 10-year median is 8.71 vs. the industry median of 5.56, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Net Margin % of 6.68% is 20.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Net Margin % is 6.68%, which is 23% below median its own 10-year median of 8.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.74, compared to a current price of BDT81.30 — trading 34.8% below its estimated fair value. The current Net Margin % is 6.68%, which is 23% below median its 10-year median of 8.71 and 20.1% above the Drug Manufacturers industry median of 5.56. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Net Margin % is 6.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Net Margin %: 6.68% (23% below median its 10-year median of 8.71)
GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
Industry Position: 20.1% above the Drug Manufacturers median (#441 of 956)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
